Compare GCTS & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCTS | VANI |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | 126 | N/A |
| Industry | Blank Checks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.5M | 100.0M |
| IPO Year | N/A | 2014 |
| Metric | GCTS | VANI |
|---|---|---|
| Price | $2.57 | $1.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.50 | $3.50 |
| AVG Volume (30 Days) | ★ 10.2M | 169.7K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | $1,052.30 | N/A |
| Revenue Next Year | $140.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.96 | $0.92 |
| 52 Week High | $3.93 | $1.92 |
| Indicator | GCTS | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 40.00 |
| Support Level | $1.25 | $0.92 |
| Resistance Level | $3.93 | $1.55 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | -0.14 | -0.02 |
| Stochastic Oscillator | 11.44 | 10.39 |
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.